Oftan (Timolol Maleate)

Timolol maleate blocks β1 and β2 adrenergic receptors in the eye’s ciliary body, which reduces the production of aqueous humor. The decrease in fluid formation lowers intra‑ocular pressure, a key factor in managing glaucoma and related conditions.

The prescribed dose of Oftan is determined by the treating eye‑care professional based on the patient’s condition, response, and tolerance. The prescriber will specify the number of drops and frequency, typically one drop per eye once or twice daily.

Timolol should be used in pregnancy or while breastfeeding only if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers evaluate each case individually and may consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Oftan (timolol) is a non‑selective beta‑blocker, offering a well‑established efficacy profile for reducing intra‑ocular pressure. Compared with prostaglandin analogues, timolol may have fewer ocular surface changes but can produce systemic beta‑blocker effects, so patient comorbidities guide the choice of therapy.

Oftan should be stored at ambient temperature, preferably below 25 °C. Keep the bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed to maintain sterility.

Oftan is applied topically to the eye. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a small pocket, and place the prescribed number of drops into the conjunctival sac. Close the eye gently and avoid blinking excessively for a few seconds.

Serious risks include systemic bradycardia, hypotension, bronchospasm in patients with asthma or COPD, severe allergic reactions, and masking of hypoglycaemic symptoms in diabetic patients. Patients should be instructed to seek immediate medical attention if they experience chest pain, severe shortness of breath, or signs of an allergic reaction.

Oftan is contraindicated in patients with known hypersensitivity to timolol or any component of the formulation, those with severe sinus bradycardia, second‑ or third‑degree heart block without a pacemaker, and individuals with uncontrolled asthma or severe chronic obstructive pulmonary disease.